Predictive Biosciences, Epigenomics extend GSTP1 licensing agreement for prostate cancer
Links shared publicly online about this topic.
- 721total visits
Predictive Biosciences, Epigenomics extend GSTP1 licensing agreement for prostate cancer
View full resource at news-medical.net
Tags: Cancer, Prostate Cancer, Prostate, Disease and Condition, Men's Health, Pathology
Most Recently Shared on November 17, 2010 at 8:17 am By:
Predictive Biosciences, Epigenomics extend GSTP1 licensing agreement for prostate cancer: Epigenomics AG , the c... http://bit.ly/cQqioX
Predictive Biosciences, Epigenomics extend GSTP1 licensing agreement for prostate cancer
news-medical.net — “Epigenomics AG , the cancer diagnostics company, and Predictive Biosciences, a commercial stage, fully-integrated developer of novel molecular diagnostic cancer assays and a provider of anatomic pathology laboratory products and services, today announced that they have extended their licensing agreement for the prostate cancer biomarker GSTP1, originally signed in April 2009.” View full resource at news-medical.net
Most Recently Shared on November 17, 2010 at 8:19 am By:
News-Medical.Net Oncology and Health News
Oncology News: Predictive Biosciences, Epigenomics extend GSTP1 licensing agreement for prostate cancer: Epigeno... http://bit.ly/cOMfa5
Advertisement
